Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study

Journal of Hepatology

Volumn 65, Issue 3, 2016, Pages 543-551

  Vandenbulcke, Hélène ^a   Moreno, Christophe ^b   Colle, Isabelle ^c   Knebel, Jean François ^d,e   Francque, Sven ^f   Sersté, Thomas ^g   George, Christophe ^h   de Galocsy, Chantal ⁱ   Laleman, Wim ^j   Delwaide, Jean ^k   Orlent, Hans ^l   Lasser, Luc ^m   Trépo, Eric ^b   Van Vlierberghe, Hans ^c   Michielsen, Peter ^f   van Gossum, Marc ^g   de Vos, Marie ^a   Marot, Astrid ⁿ   Doerig, Christopher ⁿ   Henrion, Jean ^a   Deltenre, Pierre ^b,n   more..

^a Hospital de Jolimont   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e EEG Brain Mapping Core   (Switzerland)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^g SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^h AZ GROENINGE   (Belgium)

ⁱ IRIS   (Belgium)

^j UNIVERSITY OF LEUVEN   (Belgium)

^k UNIVERSITY OF LIÈGE   (Belgium)

^l General Hospital St Jan   (Belgium)

^m BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

ⁿ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

more..

Author keywords

Alcohol intake; Cirrhosis; Decompensation; Hepatocellular carcinoma; Survival; Viral eradication

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALCOHOL; BILIRUBIN; BOCEPREVIR; CREATININE; INTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR;

ADULT; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; CANCER RISK; CAUSE OF DEATH; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT CARE; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; VIRAL CLEARANCE; DRINKING BEHAVIOR; HEPACIVIRUS; HEPATITIS B; LIVER CIRRHOSIS; LIVER TUMOR;

ALCOHOL DRINKING; CARCINOMA, HEPATOCELLULAR; ETHANOL; HEPACIVIRUS; HEPATITIS B; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84991063289     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.04.031     Document Type: Article

References (41)

1. [1] EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60 (2014), 392–420.
2. [2] Deltenre, P., Studies on the epidemiology of hepatitis B and C virus infections are still needed. J Hepatol 62 (2015), 1225–1227.
3. [3] Serfaty, L., Aumaitre, H., Chazouilleres, O., Bonnand, A.M., Rosmorduc, O., Poupon, R.E., et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 27 (1998), 1435–1440.
4. [4] Sangiovanni, A., Prati, G.M., Fasani, P., Ronchi, G., Romeo, R., Manini, M., et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 43 (2006), 1303–1310.
5. [5] Poynard, T., Bedossa, P., Opolon, P., Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997), 825–832.
6. [6] Bedogni, G., Miglioli, L., Masutti, F., Ferri, S., Castiglione, A., Lenzi, M., et al. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Am J Gastroenterol 103 (2008), 2248–2253.
7. [7] Deuffic-Burban, S., Deltenre, P., Buti, M., Stroffolini, T., Parkes, J., Muhlberger, N., et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology, 143, 2012, e14.
8. [8] Deuffic-Burban, S., Deltenre, P., Louvet, A., Canva, V., Dharancy, S., Hollebecque, A., et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol 49 (2008), 175–183.
9. [9] Thomas, D.L., Astemborski, J., Rai, R.M., Anania, F.A., Schaeffer, M., Galai, N., et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284 (2000), 450–456.
10. [10] Harris, H.E., Ramsay, M.E., Andrews, N., Eldridge, K.P., Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 324 (2002), 450–453.
11. [11] Tagger, A., Donato, F., Ribero, M.L., Chiesa, R., Portera, G., Gelatti, U., et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 81 (1999), 695–699.
12. [12] Marcellin, P., Boyer, N., Gervais, A., Martinot, M., Pouteau, M., Castelnau, C., et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 127 (1997), 875–881.
13. [13] Sobesky, R., Mathurin, P., Charlotte, F., Moussalli, J., Olivi, M., Vidaud, M., et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 116 (1999), 378–386.
14. [14] Amin, J., Law, M.G., Bartlett, M., Kaldor, J.M., Dore, G.J., Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 368 (2006), 938–945.
15. [15] Davis, G.L., Alter, M.J., El-Serag, H., Poynard, T., Jennings, L.W., Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138 (2010), 513–521 521, e1–e6.
16. [16] Cardoso, A.C., Moucari, R., Figueiredo-Mendes, C., Ripault, M.P., Giuily, N., Castelnau, C., et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 52 (2010), 652–657.
17. [17] van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2013), 2584–2593.
18. [18] Veldt, B.J., Heathcote, E.J., Wedemeyer, H., Reichen, J., Hofmann, W.P., Zeuzem, S., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147 (2007), 677–684.
19. [19] Bruno, S., Crosignani, A., Facciotto, C., Rossi, S., Roffi, L., Redaelli, A., et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 51 (2010), 2069–2076.
20. [20] Iacobellis, A., Siciliano, M., Perri, F., Annicchiarico, B.E., Leandro, G., Caruso, N., et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 46 (2007), 206–212.
21. [21] Shiratori, Y., Ito, Y., Yokosuka, O., Imazeki, F., Nakata, R., Tanaka, N., et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 142 (2005), 105–114.
22. [22] Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 (1999), 174–181.
23. [23] Innes, H.A., Hutchinson, S.J., Allen, S., Bhattacharyya, D., Bramley, P., Delahooke, T.E., et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology 54 (2011), 1547–1558.
24. [24] Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 20 (1994), 15–20.
25. [25] Castera, L., Forns, X., Alberti, A., Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48 (2008), 835–847.
26. [26] Ziol, M., Handra-Luca, A., Kettaneh, A., Christidis, C., Mal, F., Kazemi, F., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41 (2005), 48–54.
27. [27] European Association for the Study of the L. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53 (2010), 397–417.
28. [28] Jepsen, P., Vilstrup, H., Andersen, P.K., The clinical course of cirrhosis: The importance of multistate models and competing risks analysis. Hepatology 62 (2015), 292–302.
29. [29] Gray, R.J., A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988), 1141–1154.
30. [30] Campbell, J.V., Hagan, H., Latka, M.H., Garfein, R.S., Golub, E.T., Coady, M.H., et al. High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend 81 (2006), 259–265.
31. [31] White, I.R., Altmann, D.R., Nanchahal, K., Alcohol consumption and mortality: modeling risks for men and women at different ages. BMJ, 325, 2002, 191.
32. [32] Trinchet, J.C., Bourcier, V., Chaffaut, C., Ait Ahmed, M., Allam, S., Marcellin, P., et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 62 (2015), 737–750.
33. [33] Morgan, T.R., Mandayam, S., Jamal, M.M., Alcohol and hepatocellular carcinoma. Gastroenterology 127 (2004), S87–S96.
34. [34] Rigamonti, C., Mottaran, E., Reale, E., Rolla, R., Cipriani, V., Capelli, F., et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology 38 (2003), 42–49.
35. [35] McKillop, I.H., Schrum, L.W., Role of alcohol in liver carcinogenesis. Semin Liver Dis 29 (2009), 222–232.
36. [36] Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hurter, D., et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28 (1998), 1687–1695.
37. [37] Backus, L.I., Boothroyd, D.B., Phillips, B.R., Belperio, P., Halloran, J., Mole, L.A., A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol, 9, 2011, e1.
38. [38] Bruno, S., Stroffolini, T., Colombo, M., Bollani, S., Benvegnu, L., Mazzella, G., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45 (2007), 579–587.
39. [39] Mathurin, P., Deltenre, P., Effect of binge drinking on the liver: an alarming public health issue?. Gut 58 (2009), 613–617.
40. [40] Degos, F., Christidis, C., Ganne-Carrie, N., Farmachidi, J.P., Degott, C., Guettier, C., et al. Hepatitis C virus-related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 47 (2000), 131–136.
41. [41] Benvegnu, L., Gios, M., Boccato, S., Alberti, A., Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53 (2004), 744–749.